Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis

References

• Ahmad SS, Duke S, Jena R, et al. Advances in radiotherapy. Br Med J. 2012;345(1):e7765.
   PubMedGoogle Scholar
• Delaney G, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104(6):1129–1137.
   PubMed Web of Science ®Google Scholar
• Barnett GC, West CM, Dunning AM, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer. 2009;9(2):134.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Radiotherapy: gazing at the crystal ball of European radiotherapy. Nat Rev Clin Oncol. 2015;12(1):5.
   PubMed Web of Science ®Google Scholar
• Jaffray DA. Image-guided radiotherapy: from current concept to future perspectives. Nat Rev Clin Oncol. 2012;9(12):688–699.
   PubMed Web of Science ®Google Scholar
• Kuwahara Y, Roudkenar MH, Urushihara Y, et al. Clinically relevant radioresistant cell line: a simple model to understand cancer radioresistance. Med Mol Morphol. 2017;50(4):195–204.
   PubMed Web of Science ®Google Scholar
• Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer. 2011;11(4):239–253.
   PubMed Web of Science ®Google Scholar
• Shu H-KG, Kim MM, Chen P, et al. The intrinsic radioresistance of glioblastoma-derived cell lines is associated with a failure of p53 to induce p21BAX expression. Proc Nat Acad Sci. 1998;95(24):14453–14458.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25(26):4066–4074.
   PubMed Web of Science ®Google Scholar
• Ahn GO, Tseng D, Liao CH, et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Nat Acad Sci. 2010;107(18):8363–8368.
   PubMed Web of Science ®Google Scholar
• Kioi M, Vogel H, Schultz G, et al. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest. 2010;120(3):694–705.
   PubMed Web of Science ®Google Scholar
• Peach MS, Showalter TN, Ohri N. systematic review of the relationship between acute and late gastrointestinal toxicity after radiotherapy for prostate cancer. Prostate Cancer. 2015;2015.
   PubMedGoogle Scholar
• Bentzen SM, Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal tissue injury. In: Seminars in radiation oncology. Elsevier; 1994. p. 68–80. Philadelphia, PA: W.B. Saunders, United States.
   Google Scholar
• Fernet M, Hall J. Predictive markers for normal tissue reactions: fantasy or reality? Cancer Radiother. 2008;12(6–7):614–618.
   PubMed Web of Science ®Google Scholar
• Andreassen CN, Alsner J. Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol. 2009;92(3):299–309.
   PubMed Web of Science ®Google Scholar
• Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474(11):1823–1836.
   PubMed Web of Science ®Google Scholar
• Ohtani N. Microbiome and cancer. In: Seminars immunopathol. Springer; 2015. p. 65–72. Germany: Springer Berlin Heidelberg.
   Google Scholar
• Kamada N, Seo S-U, Chen GY, et al. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321–335.
   PubMed Web of Science ®Google Scholar
• Rajilić‐Stojanović M, Smidt H, De Vos WM. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol. 2007;9(9):2125–2136.
   PubMed Web of Science ®Google Scholar
• Kosiewicz MM, Zirnheld AL, Alard P. Gut microbiota, immunity, and disease: a complex relationship. Front Microbiol. 2011;2:18
   PubMed Web of Science ®Google Scholar
• Benson AK, Kelly SA, Legge R, et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Nat Acad Sci. 2010;107(44):18933–18938.
   PubMed Web of Science ®Google Scholar
• Purchiaroni F, Tortora A, Gabrielli M, et al. The role of intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci. 2013;17(3):323–333.
   PubMed Web of Science ®Google Scholar
• Carding S, Verbeke K, Vipond DT, et al. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26(1):26191.
   PubMedGoogle Scholar
• Viaud S, Daillere R, Boneca IG, et al. Gut microbiome and anticancer immune response: really hot Sh*t! Cell Death Differ. 2015;22(2):199–214.
   PubMed Web of Science ®Google Scholar
• Li J, Butcher J, Mack D, et al. Functional impacts of the intestinal microbiome in the pathogenesis of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(1):139–153.
   PubMed Web of Science ®Google Scholar
• Seekatz AM, Young VB. Clostridium difficile and the microbiota. J Clin Invest. 2014;124(10):4182–4189.
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971–976.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967–970.
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–1084.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015;350(6264):1084–1089.
   PubMed Web of Science ®Google Scholar
• Frank M, Hennenberg EM, Eyking A, et al. TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol. 2015;194(4):1983–1995.
   PubMed Web of Science ®Google Scholar
• Manichanh C, Varela E, Martinez C, et al. The gut microbiota predispose to the pathophysiology of acute postradiotherapy diarrhea. Am J Gastroenterol. 2008;103(7):1754–1761.
   PubMed Web of Science ®Google Scholar
• Nam YD, Kim HJ, Seo JG, et al. Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLoS One. 2013;8(12):e82659.
   PubMed Web of Science ®Google Scholar
• Wang A, Ling Z, Yang Z, et al. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One. 2015;10(5):e0126312.
   PubMed Web of Science ®Google Scholar
• Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017;14(6):356–365.
   PubMed Web of Science ®Google Scholar
• Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer. 2017.
   PubMed Web of Science ®Google Scholar
• Baskar R, Dai J, Wenlong N, et al. Biological response of cancer cells to radiation treatment. Front Mol Biosci. 2014;1.
   PubMedGoogle Scholar
• Najafi M, Motevaseli E, Shirazi A, et al. Mechanisms of inflammatory responses to radiation and normal tissues toxicity: clinical implications. Int J Radiat Biol. 2018;94(4):335–356.
   PubMed Web of Science ®Google Scholar
• Yahyapour R, Amini P, Rezapour S, et al. Radiation-induced inflammation and autoimmune diseases. Mil Med Res. 2018;5(1):9.
   PubMed Web of Science ®Google Scholar
• Kim JH, Jenrow KA, Brown SL. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. Radiat Oncol J. 2014;32(3):103–115.
   PubMedGoogle Scholar
• Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol. 2010;31(4):363–372.
   PubMedGoogle Scholar
• Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 2008;15(1):3–12.
   PubMed Web of Science ®Google Scholar
• Yoshimoto Y, Suzuki Y, Mimura K, et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One. 2014;9(3):e92572.
   PubMed Web of Science ®Google Scholar
• Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29(4):482.
   PubMed Web of Science ®Google Scholar
• Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691–1701.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860.
   PubMed Web of Science ®Google Scholar
• Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30(1):61–69.
   PubMed Web of Science ®Google Scholar
• Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007;28(10):429–436.
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Jammeh ML, Wattenberg MM, et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014;5(2):403–416.
   PubMed Web of Science ®Google Scholar
• Multhoff G, Pockley AG, Schmid TE, et al. The role of heat shock protein 70 (Hsp70) in radiation-induced immunomodulation. Cancer Lett. 2015;368(2):179–184.
   PubMed Web of Science ®Google Scholar
• Garg AD, Nowis D, Golab J, et al. Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation. Biochim Biophys Acta Bioenerg Reviews on Cancer. 2010;1805(1):53–71.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511.
   PubMed Web of Science ®Google Scholar
• McClure R, Massari P. TLR-dependent human mucosal epithelial cell responses to microbial pathogens. Front Immunol. 2014;5:386.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–1059.
   PubMed Web of Science ®Google Scholar
• Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type I interferon–dependent innate and adaptive immunity. Cancer Res. 2011.
   PubMedGoogle Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014.
   PubMed Web of Science ®Google Scholar
• Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–595.
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.
   PubMed Web of Science ®Google Scholar
• Yahyapour R, Amini P, Rezapoor S, et al. Targeting of inflammation for radiation protection and mitigation. Curr Mol Pharmacol. 2018;11(3):203–210.
   PubMed Web of Science ®Google Scholar
• Farhood B, Goradel NH, Mortezaee K, et al. Intercellular communications-redox interactions in radiation toxicity; potential targets for radiation mitigation. J Cell Commun Signal. 2018;13(1):3-16.
   PubMed Web of Science ®Google Scholar
• Yahyapour R, Motevaseli E, Rezaeyan A, et al. Reduction–oxidation (redox) system in radiation-induced normal tissue injury: molecular mechanisms and implications in radiation therapeutics. Clin Transl Oncol. 2018;20(8):975-988.
   PubMed Web of Science ®Google Scholar
• Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9(5):313–323.
   PubMed Web of Science ®Google Scholar
• Macpherson AJ, Hunziker L, McCoy K, et al. IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. Microbes Infect. 2001;3(12):1021–1035.
   PubMed Web of Science ®Google Scholar
• Mazmanian SK, Liu CH, Tzianabos AO, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107–118.
   PubMed Web of Science ®Google Scholar
• Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol. 2004;4(6):478–485.
   PubMed Web of Science ®Google Scholar
• O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688–693.
   PubMed Web of Science ®Google Scholar
• Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Nat Acad Sci. 2010;107(27):12204–12209.
   PubMed Web of Science ®Google Scholar
• Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139(3):485–498.
   PubMed Web of Science ®Google Scholar
• Arpaia N, Campbell C, Fan X, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. 2013;504(7480):451–455.
   PubMed Web of Science ®Google Scholar
• Forbes JD, Van Domselaar G, Bernstein CN. The gut microbiota in immune-mediated inflammatory diseases. Front Microbiol. 2016;7.
   PubMed Web of Science ®Google Scholar
• Wu H-J, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32(6):815–827.
   PubMed Web of Science ®Google Scholar
• Bultman SJ. Emerging roles of the microbiome in cancer. Carcinogenesis. 2013;35(2):249–255.
   PubMed Web of Science ®Google Scholar
• Kim YS, Kim J, Park SJ. High-throughput 16S rRNA gene sequencing reveals alterations of mouse intestinal microbiota after radiotherapy. Anaerobe. 2015;33:1–7.
   PubMed Web of Science ®Google Scholar
• Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40(5):409–421.
   PubMed Web of Science ®Google Scholar
• Pflug N, Kluth S, Vehreschild JJ, et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota. OncoImmunology. 2016;5:6.
   Web of Science ®Google Scholar
• Crawford PA, Gordon JI. Microbial regulation of intestinal radiosensitivity. Proc Natl Acad Sci U S A. 2005;102(37):13254–13259.
   PubMed Web of Science ®Google Scholar
• Cui M, Xiao H, Luo D, et al. Circadian rhythm shapes the gut microbiota affecting host radiosensitivity. Int J Mol Sci. 2016;17:11.
   Web of Science ®Google Scholar
• Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest. 2007;117(8):2197–2204.
   PubMed Web of Science ®Google Scholar
• Chan S, Rowbottom L, McDonald R, et al. Does the time of radiotherapy affect treatment outcomes? A review of the literature. Clin Oncol (R Coll Radiol). 2017;29(4):231–238.
   PubMed Web of Science ®Google Scholar
• Group EGW, Peterson D, R-J B, Roila F. Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol. 2011;22(suppl_6):vi78–vi84.
   PubMedGoogle Scholar
• Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy‐induced mucosal injury. Cancer. 2004;100(S9):1995–2025.
   PubMedGoogle Scholar
• Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients with cancer. Dent Clin North Am. 2008;52(1):61–viii.
   PubMedGoogle Scholar
• Ortiz F, Acuña‐Castroviejo D, Doerrier C, et al. Melatonin blunts the mitochondrial/NLRP 3 connection and protects against radiation-induced oral mucositis. J Pineal Res. 2015;58(1):34–49.
   PubMed Web of Science ®Google Scholar
• Wardill HR, Tissing WJE. Determining risk of severe gastrointestinal toxicity based on pretreatment gut microbial community in patients receiving cancer treatment: a new predictive strategy in the quest for personalized cancer medicine. Curr Opin Support Palliat Care. 2017;11(2):125–132.
   PubMed Web of Science ®Google Scholar
• van Vliet MJ, Harmsen HJM, de Bont ESJM, et al. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010;6(5):1–7.
   Web of Science ®Google Scholar
• Abayomi J, Kirwan J, Hackett A, et al. A study to investigate women’s experiences of radiation enteritis following radiotherapy for cervical cancer. J Hum Nutr Diet. 2005;18(5):353–363.
   PubMed Web of Science ®Google Scholar
• Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr. 2014;33(5):761–767.
   PubMed Web of Science ®Google Scholar
• Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. Tumori. 2007;93(suppl 2):1–6.
   PubMedGoogle Scholar
• Linn YH, Thu KK, Win NHH. Effect of probiotics for the prevention of acute radiation-induced diarrhoea among cervical cancer patients: a randomized double-blind placebo-controlled study. Probiotics Antimicrob Proteins. 2018.
   PubMedGoogle Scholar
• Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120(10):1453–1461.
   PubMed Web of Science ®Google Scholar
• Wardill HR, Van Sebille YZ, Ciorba MA, et al. Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. Curr Opin Support Palliat Care. 2018;12(2):187–197.
   PubMed Web of Science ®Google Scholar
• Wardill HR, Gibson RJ, Van Sebille YZ, et al. Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Mol Cancer Ther. 2016;15(6):1376–1386.
   PubMed Web of Science ®Google Scholar
• Riehl T, Cohn S, Tessner T, et al. Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology. 2000;118(6):1106–1116.
   PubMed Web of Science ®Google Scholar
• Riehl TE, Newberry RD, Lorenz RG, et al. TNFR1 mediates the radioprotective effects of lipopolysaccharide in the mouse intestine. Am J Physiol Gastrointest Liver Physiol. 2004;286(1):G166–G73.
   PubMed Web of Science ®Google Scholar
• Egan LJ, Eckmann L, Greten FR, et al. IκB-kinaseβ-dependent NF-κB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci U S A. 2004;101(8):2452–2457.
   PubMed Web of Science ®Google Scholar
• Vanhoecke B, De Ryck T, Stringer A, et al. Microbiota and their role in the pathogenesis of oral mucositis. Oral Dis. 2015;21(1):17–30.
   PubMed Web of Science ®Google Scholar
• Elting LS, Cooksley CD, Chambers MS, et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110–1120.
   PubMed Web of Science ®Google Scholar
• Trotti A, Bellm LA, Epstein JB, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253–262.
   PubMed Web of Science ®Google Scholar
• Maria OM, Eliopoulos N, Muanza T. Radiation-induced oral mucositis. Front Oncol. 2017;7.
   PubMed Web of Science ®Google Scholar
• Eilers J, Million R. Prevention and management of oral mucositis in patients with cancer. In: Seminars in oncology nursing. Elsevier; 2007. p. 201–212. Philadelphia, PA: W.B. Saunders, United States.
   Google Scholar
• Pratesi N, Mangoni M, Mancini I, et al. Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer. Radiother Oncol. 2011;99(3):356–361.
   PubMed Web of Science ®Google Scholar
• Ren J-H, Dai X-F, Yan G-L, et al. Acute oral mucositis in nasopharyngeal carcinoma patients treated with radiotherapy: association with genetic polymorphism in DNA DSB repair genes. Int J Radiat Biol. 2014;90(3):256–261.
   PubMed Web of Science ®Google Scholar
• Brzozowska A, Powrózek T, Homa-Mlak I, et al. Polymorphism of promoter region of TNFRSF1A gene (− 610 T> G) as a novel predictive factor for radiotherapy induced oral mucositis in hnc patients. Pathol Oncol Res. 2018;24(1):135–143.
   PubMed Web of Science ®Google Scholar
• Le Z, Niu X, Chen Y, et al. Predictive single nucleotide polymorphism markers for acute oral mucositis in patients with nasopharyngeal carcinoma treated with radiotherapy. Oncotarget. 2017;8(38):63026.
   PubMedGoogle Scholar
• Vanhoecke BW, De Ryck TR, De Boel K, et al. Low-dose irradiation affects the functional behavior of oral microbiota in the context of mucositis. Exp Biol Med. 2016;241(1):60–70.
   Web of Science ®Google Scholar
• Zhu XX, Yang XJ, Chao YL, et al. The potential effect of oral microbiota in the prediction of mucositis during radiotherapy for nasopharyngeal carcinoma. EBioMedicine. 2017;18:23–31.
   PubMed Web of Science ®Google Scholar
• Wijers OB, Levendag PC, Harms ER, et al. Mucositis reduction by selective elimination of oral flora in irradiated cancers of the head and neck: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys. 2001;50(2):343–352.
   PubMed Web of Science ®Google Scholar
• Stokman MA, Spijkervet FK, Burlage FR, et al. Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomised clinical trial. Br J Cancer. 2003;88(7):1012–1016.
   PubMed Web of Science ®Google Scholar
• Saunders DP, Epstein JB, Elad S, et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3191–3207.
   PubMed Web of Science ®Google Scholar
• Sharma A, Rath G, Chaudhary S, et al. Lactobacillus brevis CD2 lozenges reduce radiation-and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur J Cancer. 2012;48(6):875–881.
   PubMed Web of Science ®Google Scholar
• Nagler R. The enigmatic mechanism of irradiation‐induced damage to the major salivary glands. Oral Dis. 2002;8(3):141–146.
   PubMed Web of Science ®Google Scholar
• Eliasson L, Carlén A, Almståhl A, et al. Dental plaque pH and micro-organisms during hyposalivation. J Dent Res. 2006;85(4):334–338.
   PubMed Web of Science ®Google Scholar
• Andrews N, Griffiths C. Dental complications of head and neck radiotherapy: part 1. Aust Dent J. 2001;46(2):88–94.
   PubMed Web of Science ®Google Scholar